Status: Enrolling
Investigator: Warren Ellsworth
Study Coordinator: Valentina Villarroel
Phone: 346.238.4384
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Open Not Enrolling
Investigator: Bincy Abraham
Study Coordinator: Zinah Rasheed
Phone: 713.363.7536
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >
Status: Enrolling
Investigator: Aldona Spiegel
Study Coordinator: Valentina Villarroel
Phone: 346.238.4384
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator:
Phone:
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC). ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease. ... Read more >
Status: Open Not Enrolling
Investigator: Nabil Tariq
Study Coordinator:
Phone:
This study is designed to evaluate the post-operative complications and re-herniations following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.</ ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator:
Phone:
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >
Status: Open Not Enrolling
Investigator: David Victor
Study Coordinator: Nicole Hinton
Phone: 281.755.0796
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH). ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease. ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator: Mayyadah Al-Sabbagh
Phone: 346.238.0307
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >
Status: Open Not Enrolling
Investigator: Marvin Atkins
Study Coordinator: Sanjana Tabassum
Phone: 346.238.8240
This study is a prospective, multicenter, non-randomized single-arm study to assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® TAG® Thoracic Branch Endoprosthesis system. ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Jennifer Lee
Phone: 713.363.7537
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease. ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator:
Phone:
Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N- ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 713.441.3771
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to at ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator: Lindsay Barter
Phone: 502.417.6664
The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steat ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator: Mayyadah Al-Sabbagh
Phone: 346.238.0307
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part ... Read more >
Status: Enrolling
Investigator: Masayoshi Takashima
Study Coordinator: Tariq Syed
Phone: 346.238.6466
The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial. ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Ana Lucia Varon Ocampo
Phone: 713.441.7182
Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Ana Lucia Varon Ocampo
Phone: 713.441.7182
Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator: Miguel Valdivia y Alvarado
Phone: 346.238.2626
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which t ... Read more >
Status: Open Not Enrolling
Investigator: Laila Tabatabai
Study Coordinator: Melissa Whipple
Phone: 713.441.3247
The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of buro ... Read more >